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Medical and microbiology records of seventeen patients (17 eyes), diagnosed as scleritis of infectious origin were reviewed; to
study clinical features, predisposing risk factors, microbiologic proﬁle and treatment outcome of infectious scleritis. The mean
patient age was 52.3 ± 19.75 years. Twelve patients (70.6%) had history of trauma/prior surgery. Isolated organisms included
Staphylococcus species (spp) (n = 5), Fungus (n = 4), Nocardia spp (n = 3), two each of atypical Mycobacterium spp and
Streptococcus pneumoniae and one Pseudomonas aeruginosa. Treatment included intensive topical antimicrobial in all eyes and
systemic medication in 15(88.2%) patients; surgical exploration was needed for 13(76.5%) patients and scleral patch graft was
done in four (23.5%) patients. Lesions resolved in all patients and none required evisceration. The presenting log MAR visual
acuity of 1.77 ± 1.4 0a n di m p r o v e dt o0 .99 ± 0.91. (P ≤ 0.039) after treatment with a mean follow up of 22.57 ± 19.53 weeks. A
microbiological conﬁrmation, appropriate medical and/or surgical intervention has a good tectonic and visual outcome.
1.Introduction
Infectious scleritis presents as an ulcerated or nonulcerated,
inﬂamedscleralnodule[1].Itaccountsfor5–10%ofallcases
of scleritis [2–5]. But the presenting picture of infectious
scleritis may not diﬀer too much from immune-mediated
scleritis [6–10]. Approximately 40–90% of immune medi-
ated scleritis have an associated systemic vascular disease
[3, 4, 6, 10]. While systemic treatment with corticosteroids
or immunosuppressant beneﬁts immune-mediated scleritis,
it worsens the infectious scleritis. Hence it is imperative to
diﬀerentiate between two conditions.
Many authors have reported infection by Pseudomonas
aeruginosa and fungus as the most common causative
organism [1, 11–13]. Pterygium surgery with beta radiation
or application of mitomycin C has been identiﬁed as a
common risk factor for infectious scleritis [11–13].
The clinical outcome is generally poor and most cases
required evisceration in the many series [8, 9, 14]. Systemic
and topical medication combined with early surgical inter-
vention have improved the anatomical success, but not the
visual outcome in two other series [1, 12].
Infectious scleritis is a rare entity; hence it is not
suspected at the initial presentation resulting in delayed
diagnosisandtreatment.Inthiscommunication,wedescribe
the predisposing factors, clinical features, etiology, and
treatment outcome of infectious scleritis.
2.MaterialandMethod
We retrospectively reviewed the medical and microbiolog-
ical records of all patients with microbiologically proven
infectious scleritis examined at Cornea Services of L V
Prasad Eye Institute Bhubaneswar from November 2006 to
August 2009. At presentation, all patients had received a
detailed ophthalmic examination in the oﬃce. Patients with
ulcerative lesions had received a scraping with a no. 152 International Journal of Inﬂammation
surgical blade on a Bard Parker handle from the base and
activeedgesoftheulcerundertopicalanesthesiaintheoﬃce,
and all nonulcerative nodular abscesses had received scleral
scraping in the operating room under peribulbar anesthesia.
In the later case, the base of the lesion was scrapped after
dissecting the conjunctiva and derooﬁng of the nodular
lesion. Materials collected from the lesions were smeared
on glass slides and stained with Potassium hydroxide +
Calcoﬂour white stain, Grams stain, Zeihl Neelsen stain
using 20% H2SO4 or modiﬁed Zeihl Neelsen stain using
1% H2SO4. Acid fast staining was usually done if Grams
stain smear was negative, but the lesions were strongly
suspicious of microbial origin. The exudates from the lesion
were cultured on blood agar, chocolate agar, Sabouraud’s
dextrose agar (SDA), Brain-heart infusion broth and non-
nutrient agar with an Escherichia coli overlay. All media were
incubated at 37◦C except SDA; this was incubated at 27◦C.
Signiﬁcant growth was deﬁned as conﬂuent growth on solid
media, and/or there was growth of the same organism on
more than one medium, and/or growth in one medium was
accompanied by presence of similar organism in smears. All
bacteria and fungi grown were identiﬁed as per standard
protocol,andbacteriaweretestedforantibioticsusceptibility
by Kirby-Bauer disc diﬀusion method.
The initial therapy either was based on results of smear
or when smear was negative, an empirical treatment with
topical antibiotic (mostly gatiﬂoxacin 0.3% and amikacin
2.5%)alongwithsystemicgatiﬂoxacin((400mg)twicedaily)
was given. The treatment was modiﬁed, if needed, based
on ﬁnal culture and sensitivity report. Surgical debridement
was done should the scleral ulceration area extend locally or
progressed to form a subconjunctival abscess at another site
away from the main lesion.
The collected retrospective data included patient demog-
raphy (age, gender, occupation), disease history (onset,
course, predisposing factors), clinical feature, type of organ-
isms, antibiotic susceptibility, treatment given, and the
outcome.
3. Results
We included 17 patients (17 eyes) of infectious scleritis
between November 2006 and August 2009. The inclusion
criteria were presentation with a scleral ulcer and/or abscess
and an organism isolated microbiologically. This included
7 women and 10 men; the age ranged from 13 years to 75
years (mean 52.3 ± 19.75 years, median 55 years). (Table 1)
The mean followup was 22.57 ± 19.53 weeks (range of 3–89
weeks).
The most common predisposing factor was an ocular
surgery [n = 9; 52.9%. 95% (CI), 29.27–76.73]. The surgery
included cataract in seven eyes, scleral buckle in one eye,
and trabeculectomy in one eye. The interval from surgery
to diagnosis of infectious scleritis ranged from one week to
four years. Four patients had injury with organic material
like wood and mud three weeks to seven months prior
to presentation (mean 37 ± 33.04 days; median 21 days).
Fifteen of 17 patients were using topical corticosteroids and
two patients were using oral corticosteroids at the time of
reporting to us. Only one patient was diabetic in this series.
The symptoms present in all patients were redness, pain,
and watering in the aﬀected eye. The presenting visual acuity
variedfromhandmotions(HM)toanormalvisionof20/20.
Twelve patients (70.54%) presented with a vision less than
20/40. Unifocal or multifocal scleral abscess was seen in six
patients (35.39%) (Figures 1(a) and 1(b)). Characteristically,
the abscesses presented as yellowish nodules under the intact
conjunctival epithelium. Scleral ulceration and necrosis was
seen in eight patients (47.05%) (Figures 1(c) and 1(d)).
Necrosis around the incisional area was seen in all seven
patients who had received cataract surgery earlier. Three eyes
(17.34%) had both ulceration and abscess (Figure 2(a)).
The culture grew a variety of organisms. They included
Staphylococcus species (n = 5; 29.41%), fungus (n = 4;
23.52%), Nocardia species (n = 3; 17.6%), Streptococcus
pneumoniae (n = 2), atypical Mycobacterium (n = 2),
and Pseudomonas aeruginosa (n = 1). One of the four
Staphylococcus was methicillin resistant (no. 7). Of the four
fungi isolated, two could not be identiﬁed, one belonged to
Fusarium and Paecilomyces species each.
Theresultsofantibioticsusceptibilitytestingforbacterial
isolates (Kirby Bauer disc diﬀusion method) are given in
Table 2. Staphylococcal and streptococcal cases were treated
with fortiﬁed Cefazolin (50mg/mL) and a ﬂouroquinolone
(ciproﬂoxacin 0.3%/gatiﬂoxacin 0.3%) along with systemic
ﬂuoroquinolones (ciproﬂoxacin 500mg/gatiﬂoxacin 400mg
twice daily). Patient no. 7 was treated only with topi-
cal ciproﬂoxacin. Fungal scleritis was treated with topical
natamycin 5% and systemically either itraconazole (100mg)
or ketoconazole (200mg) two times daily. Nocardia and
atypical Mycobacterium scleritis were treated primarily with
topical fortiﬁed amikacin (25mg/mL). Systemic trimetho-
prim (160mg) sulphamethoxazole (800mg) (TMX-SMZ)
combination was used in patients of Nocardia scleritis only.
Thirteen of the 17 patients underwent wound debride-
ment. During the surgical debridement, it was noticed that
the area actually involved was generally much larger than
initially seen under slit lamp. N-Butyl Cyanoacrylate glue
was used in two patients as there was a limbal perforation
of less than 1mm × 1mm in size. Five patients received
scleral patch graft; as primary procedure in one (patient
no. 4, Figure 1(c)), and the remaining four eyes, 2 days to
one month after initiation of medical treatment. Seven eyes
needed multiple surgical interventions.
Oral corticosteroid (1mg/kg of body weight) was used
in 5 eyes with bacterial scleritis two days after antibacterial
treatment. In case no. 4, scleral patch graft was done as
the primary procedure, later fungal ﬁlaments were identiﬁed
from smear; so corticosteroids were started only after
two weeks when recurrence was not noticed. Intraocular
antibiotic was used in three patients suspected to have
endophthalmitis. All of them presented scleral infection after
cataract surgery.
Resolution was deﬁned as absence of symptoms, con-
gestion, or active inﬁltrate. All the patients in this series
responded to treatment; 13(76.47%) patients had only
scarring with no or minimal uveal show; one patientInternational Journal of Inﬂammation 3
T
a
b
l
e
1
:
P
a
t
i
e
n
t
d
e
m
o
g
r
a
p
h
i
c
,
c
l
i
n
i
c
a
l
,
a
n
d
m
i
c
r
o
b
i
o
l
o
g
i
c
a
l
f
e
a
t
u
r
e
,
m
a
n
a
g
e
m
e
n
t
,
a
n
d
o
u
t
c
o
m
e
.
S
l
.
n
o
.
A
g
e
S
e
x
E
y
e
H
i
s
t
o
r
y
D
u
r
a
t
i
o
n
o
f
s
y
m
p
t
o
m
s
(
i
n
d
a
y
s
)
P
r
e
s
e
n
t
i
n
g
v
i
s
u
a
l
a
c
u
i
t
y
C
l
i
n
i
c
a
l
s
i
g
n
s
O
r
g
a
n
i
s
m
T
r
e
a
t
m
e
n
t
F
i
n
a
l
v
i
s
u
a
l
a
c
u
i
t
y
R
e
m
a
r
k
s
O
u
t
c
o
m
e
T
o
p
i
c
a
l
S
y
s
t
e
m
i
c
S
u
r
g
i
c
a
l
1
.
7
2
M
O
S
C
a
t
a
r
a
c
t
s
u
r
g
e
r
y
4
5
C
F
2
m
N
e
c
r
o
s
i
s
,
c
o
r
n
e
a
l
i
n
ﬁ
l
t
r
a
t
e
S
.
a
u
r
e
u
s
F
.
c
e
f
a
z
o
l
i
n
,
c
i
p
r
o
ﬂ
o
x
a
c
i
n
C
i
p
r
o
ﬂ
o
x
a
c
i
n
T
A
+
B
C
l
2
0
/
7
0
C
o
r
n
e
a
l
s
c
a
r
R
e
s
o
l
v
e
d
2
.
6
5
M
O
D
N
i
l
6
0
2
0
/
4
0
A
b
s
c
e
s
s
N
o
c
a
r
d
i
a
s
p
p
.
F
.
a
m
i
k
a
c
i
n
,
g
a
t
i
ﬂ
o
x
a
c
i
n
T
M
X
-
S
M
Z
E
x
p
l
o
r
a
t
i
o
n
-
2
2
0
/
6
0
p
C
a
t
a
r
a
c
t
R
e
s
o
l
v
e
d
3
.
1
9
F
O
S
N
i
l
1
5
0
2
0
/
2
5
P
u
n
c
h
e
d
o
u
t
u
l
c
e
r
A
t
y
p
i
c
a
l
m
y
c
o
b
a
c
t
e
r
i
u
m
F
.
a
m
i
k
a
c
i
n
,
c
i
p
r
o
ﬂ
o
x
a
c
i
n
T
M
X
-
S
M
Z
,
p
r
e
d
n
i
s
o
l
o
n
e
N
i
l
2
0
/
3
0
C
o
r
n
e
a
l
i
n
ﬁ
l
t
r
a
t
e
,
c
h
o
r
o
i
d
a
l
R
e
s
o
l
v
e
d
4
.
7
2
M
O
S
C
a
t
a
r
a
c
t
s
u
r
g
e
r
y
4
5
C
F
2
m
N
e
c
r
o
s
i
s
F
u
s
a
r
i
u
m
s
p
p
.
N
a
t
a
m
y
c
i
n
,
g
a
t
i
ﬂ
o
x
a
c
i
n
,
c
y
c
l
o
s
p
o
r
i
n
e
I
t
r
a
c
o
n
a
z
o
l
e
S
P
G
2
0
/
1
2
0
G
r
a
f
t
v
a
s
c
u
l
a
r
i
z
e
d
R
e
s
o
l
v
e
d
5
.
3
5
F
O
D
I
n
j
u
r
y
(
w
i
t
h
s
t
i
c
k
)
1
5
C
F
2
m
A
b
s
c
e
s
s
,
c
o
r
n
e
a
l
i
n
ﬁ
l
t
r
a
t
e
F
u
n
g
u
s
N
a
t
a
m
y
c
i
n
,
g
a
t
i
ﬂ
o
x
a
c
i
n
I
t
r
a
c
o
n
a
z
o
l
e
E
x
p
l
o
r
a
t
i
o
n
,
I
n
t
r
a
c
a
m
-
e
r
a
l
a
m
p
h
o
-
B
2
0
/
1
6
0
C
o
r
n
e
a
l
s
c
a
r
a
n
d
c
a
t
a
r
a
c
t
R
e
s
o
l
v
e
d
6
.
6
6
M
O
D
C
a
t
a
r
a
c
t
s
u
r
g
e
r
y
9
H
M
S
c
l
e
r
a
l
n
e
c
r
o
s
i
s
,
e
x
u
d
a
t
e
S
.
p
n
e
u
m
o
n
i
a
e
F
.
c
e
f
a
z
o
l
i
n
,
g
a
t
i
ﬂ
o
x
a
c
i
n
,
b
e
t
a
m
e
t
h
a
s
o
n
e
L
i
z
o
l
i
d
i
n
e
,
p
r
e
d
i
n
i
s
o
l
o
n
e
S
P
G
+
I
O
A
B
2
0
/
6
0
G
r
a
f
t
v
a
s
c
u
l
a
r
i
z
e
d
R
e
s
o
l
v
e
d
7
.
4
9
M
O
D
N
i
l
1
2
0
2
0
/
2
0
U
l
c
e
r
,
a
b
s
c
e
s
s
,
t
h
i
n
n
i
n
g
S
t
a
p
h
y
l
o
c
o
c
c
u
s
s
p
p
.
C
i
p
r
o
ﬂ
o
x
a
c
i
n
,
p
r
e
d
n
i
s
o
l
o
n
e
P
r
e
d
n
i
s
o
l
o
n
e
N
i
l
2
0
/
2
0
N
i
l
R
e
s
o
l
v
e
d
8
.
5
0
M
O
S
C
a
t
a
r
a
c
t
s
u
r
g
e
r
y
7
H
M
N
e
c
r
o
s
i
s
S
.
a
u
r
e
u
s
F
.
c
e
f
a
z
o
l
i
n
,
c
i
p
r
o
ﬂ
o
x
a
c
i
n
G
a
t
i
ﬂ
o
x
a
c
i
n
S
P
G
+
V
i
t
r
e
o
u
s
b
i
o
p
s
y
+
I
O
A
B
2
0
/
1
0
0
G
r
a
f
t
v
a
s
c
u
-
l
a
r
i
z
e
d
,
c
o
r
n
e
a
l
s
c
a
r
R
e
s
o
l
v
e
d
9
.
7
4
F
O
S
I
n
j
u
r
y
(
w
i
t
h
m
u
d
)
1
5
H
M
A
b
s
c
e
s
s
P
.
a
e
r
u
g
i
n
o
s
a
F
.
a
m
i
k
a
c
i
n
,
C
i
p
r
o
ﬂ
o
x
a
c
i
n
,
P
r
e
d
n
i
s
o
l
o
n
e
C
i
p
r
o
ﬂ
o
x
a
c
i
n
,
p
r
e
d
n
i
s
o
l
o
n
e
E
x
p
l
o
r
a
t
i
o
n
2
0
/
2
0
0
C
a
t
a
r
a
c
t
,
c
h
o
r
o
i
d
a
l
R
e
s
o
l
v
e
d4 International Journal of Inﬂammation
T
a
b
l
e
1
:
C
o
n
t
i
n
u
e
d
.
S
l
.
n
o
.
A
g
e
S
e
x
E
y
e
H
i
s
t
o
r
y
D
u
r
a
t
i
o
n
o
f
s
y
m
p
t
o
m
s
(
i
n
d
a
y
s
)
P
r
e
s
e
n
t
i
n
g
v
i
s
u
a
l
a
c
u
i
t
y
C
l
i
n
i
c
a
l
s
i
g
n
s
O
r
g
a
n
i
s
m
T
r
e
a
t
m
e
n
t
F
i
n
a
l
v
i
s
u
a
l
a
c
u
i
t
y
R
e
m
a
r
k
s
O
u
t
c
o
m
e
T
o
p
i
c
a
l
S
y
s
t
e
m
i
c
S
u
r
g
i
c
a
l
1
0
.
5
0
F
O
D
I
n
j
u
r
y
(
w
i
t
h
t
w
i
g
)
7
5
2
0
/
3
0
C
h
e
m
o
s
i
s
,
a
b
s
c
e
s
s
N
o
c
a
r
d
i
a
s
p
p
.
F
.
a
m
i
k
a
c
i
n
,
c
i
p
r
o
ﬂ
o
x
a
c
i
n
C
i
p
r
o
ﬂ
o
x
a
c
i
n
E
x
p
l
o
r
a
t
i
o
n
S
P
G
+
A
M
G
2
0
/
2
0
G
r
a
f
t
v
a
s
c
u
l
a
r
i
z
e
d
R
e
s
o
l
v
e
d
1
1
.
1
3
M
O
D
T
r
a
b
e
c
u
l
e
c
t
o
m
y
3
0
C
F
1
m
A
b
s
c
e
s
s
S
.
a
u
r
e
u
s
F
.
c
e
f
a
z
o
l
i
n
,
g
a
t
i
ﬂ
o
x
a
c
i
n
C
e
f
a
d
r
o
x
i
l
N
i
l
C
F
1
m
G
l
a
u
c
o
m
a
,
o
p
t
i
c
a
t
r
o
p
h
y
R
e
s
o
l
v
e
d
1
2
.
2
1
M
O
S
T
h
y
r
o
i
d
O
p
h
t
h
a
l
m
o
p
l
e
g
i
a
N
o
t
a
v
a
i
l
a
b
l
e
2
0
/
2
0
A
b
s
c
e
s
s
S
.
p
n
e
u
m
o
n
i
a
e
F
.
g
e
n
t
a
m
i
c
i
n
,
c
h
l
o
r
a
m
p
h
e
n
i
c
o
l
P
r
e
d
n
i
s
o
l
o
n
e
N
i
l
2
0
/
3
0
N
i
l
R
e
s
o
l
v
e
d
1
3
.
5
3
M
O
S
R
e
t
i
n
a
l
d
e
t
a
c
h
m
e
n
t
s
u
r
g
e
r
y
(
b
u
c
k
l
e
)
6
0
C
F
1
m
U
l
c
e
r
,
a
b
s
c
e
s
s
A
t
y
p
i
c
a
l
m
y
c
o
b
a
c
t
e
r
i
u
m
F
.
a
m
i
k
a
c
i
n
,
g
a
t
i
ﬂ
o
x
a
c
i
n
G
a
t
i
ﬂ
o
x
a
c
i
n
B
B
R
e
m
o
v
a
l
H
M
E
l
e
v
a
t
e
d
G
r
a
n
u
l
o
m
a
R
e
s
o
l
v
e
d
1
4
.
5
5
F
O
S
N
i
l
6
0
2
0
/
2
0
0
T
h
i
n
n
i
n
g
,
u
l
c
e
r
,
a
b
s
c
e
s
s
N
o
c
a
r
d
i
a
s
p
p
.
F
.
a
m
i
k
a
c
i
n
,
c
i
p
r
o
ﬂ
o
x
a
c
i
n
C
i
p
r
o
ﬂ
o
x
a
c
i
n
,
T
M
X
-
S
M
Z
E
x
p
l
o
r
a
t
i
o
n
-
3
2
0
/
5
0
N
i
l
R
e
s
o
l
v
e
d
1
5
.
7
5
F
O
D
C
a
t
a
r
a
c
t
s
u
r
g
e
r
y
6
0
H
M
N
e
c
r
o
s
i
s
F
u
n
g
u
s
N
a
t
a
m
y
c
i
n
I
t
r
a
c
o
n
a
z
o
l
e
T
A
+
B
C
L
2
0
/
5
0
C
o
r
n
e
a
l
s
c
a
r
R
e
s
o
l
v
e
d
1
6
.
6
5
F
O
S
C
a
t
a
r
a
c
t
s
u
r
g
e
r
y
7
2
0
/
7
0
N
e
c
r
o
s
i
s
,
c
o
r
n
e
a
l
i
n
ﬁ
l
t
r
a
t
e
S
.
a
u
r
e
u
s
F
.
c
e
f
a
z
o
l
i
n
,
g
a
t
i
ﬂ
o
x
a
c
i
n
,
p
r
e
d
n
i
s
o
l
o
n
e
C
i
p
r
o
ﬂ
o
x
a
c
i
n
W
o
u
n
d
r
e
p
a
i
r
+
I
O
A
B
2
0
/
4
0
M
e
m
b
r
a
n
e
o
v
e
r
I
O
L
R
e
s
o
l
v
e
d
1
7
.
5
5
M
O
S
C
a
t
a
r
a
c
t
s
u
r
g
e
r
y
3
0
2
0
/
1
6
0
N
e
c
r
o
s
i
s
P
a
e
c
i
l
o
m
y
c
e
s
s
p
p
.
N
a
t
a
m
y
c
i
n
K
e
t
o
c
o
n
a
z
o
l
e
S
P
G
P
L
+
P
u
p
i
l
l
a
r
y
m
e
m
b
r
a
n
e
R
e
s
o
l
v
e
dInternational Journal of Inﬂammation 5
(a) (b)
(c) (d)
Figure 1: Slit lamp picture depicting diﬀerent clinical presentation. (a) Case no. 2: multiple scleral abscess. (b) Case no.12: single scleral
abscess. (c) Case no. 4: necrotic ulcer (post cataract surgery). (d) Case no. 3: two punched out ulcers.
(a) (b) (c)
Figure 2: Slit lamp picture of Case no. 10. (a) At Presentation showing multiple abscesses and ulcer. (b) Three weeks after initiation of
treatment (surgical exploration and medical management), there is a uveal show. (c) Final outcome showing vascularized scleral graft (four
months after scleral patch graft).
required scleral patch graft (Patient no. 10 Figures 2(a),
2(b),a n d2(c)) one month after initiation of treatment. In
the patients where scleral patch graft was done, success was
deﬁned as no evidence of graft or surrounding inﬁltrate and
vascularization of the graft. All ﬁve grafts were healthy at the
last visit.
The mean presenting and post treatment logMAR visual
acuity was 1.77 ± 1.40 and 0.99 ± 0.91. (P ≤ 0.039)
(Figure 3). The vision improved by greater than 2 lines in 8
of 12 patients who presented with a visual acuity of <20/40
patients.
The primary cause of decreased vision after resolution
of infection was cataract and corneal scar. Total choroidal
detachment developed in two patients and was treated with
tapering oral corticosteroids. One of the two patients had
atypical Mycobacteria infection. This 19-year-old lady also
developed a corneal abscess after seven months of treatment.
It resolved with topical fortiﬁed amikacin.
4. Discussion
Scleritis may represent a diagnostic challenge and is often
associated with life-threatening systemic disease (in this
series, only one patient had diabetes mellitus though) and
vision-threatening ocular complications [15].
Scleral infection from Pseudomonas, Staphylococcus,o r
Herpes zoster virus can cause necrotizing scleritis, which
is clinically identical to systemic autoimmune disease [6].6 International Journal of Inﬂammation
Table 2: Results of antibiotic susceptibility testing for bacterial isolates (Kirby Bauer disc diﬀusion method).
Sl. no Patient no.
(from Table 1) Name of the bacteria Antibiotics
Chlo Cefa Vanco Cipro Gati Oﬂo Amik
11 S. aureus S N DN DS S N DN D
22 Nocardia s p . SSN D SSN D S
3 3 Atypical mycobacteria S S S S S ND S
46 S. pneumoniae SSSSSSN D
57 Staphylococcus s p .SSSRSIN D
68 S. aureus SSSIIIN D
79 P. aeruginosa R N DN DS S S S
81 0 Nocardia s p . RRRSSSS
91 1 S. aureus RSSRIIN D
10 12 S. pneumoniae SSSSSSN D
1 1 1 3 A t y p i c a l m y c o b a c t e r i a RRRRRRS
12 14 Nocardia s p . SRSRSRS
13 16 S. aureus SSSISIN D
Chlo: Chloramphenicol, Cefa: Cefazolin, Vanco: Vancomycin, Cipro: Ciproﬂoxacin, Gati: Gatiﬂoxacin, Oﬂox: Oﬂoxacin, Amik: Amikacin, S: Sensitive, I:
Intermediate, R: Resistant, ND: Not done.
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Figure 3: Comparision of the presenting visual acuity with
posttreatment logMAR visual acuity of all patients.
Unusual organisms like Nocardia, Acanthamoeba, atypical
Mycobacteria,Mycobacteriumtuberculosis,andListeriamono-
cytogenes are known to cause scleritis [1, 16–18]. Often the
diagnosis of an associated infection or systemic condition
dictates therapy. Systemic vasculitis typically requires sys-
temic corticosteroid or immunosuppressive drugs [2, 3].
An early and deﬁnitive diagnosis helps in treatment of the
condition and has better outcome.
Patients with a history of prior ocular surgery or trauma
and presenting with a scleral abscess or ulceration and
necrosis should arouse the suspicion of infectious origin.
The surgeries include pterygium, cataract, scleral buckling,
and strabismus surgery [10–12, 18]. In our series, cataract
surgery was the predisposing factor in seven eyes and trauma
with organic material was present in four eyes.
Corticosteroids, given before infection control, in an
infectious scleritis worsen the condition by inhibiting release
of lysosomal enzyme. In this cohort, 15 of 17 patients
were on topical corticosteroids at presentation to us. It is
unknown whether this aggravated the infection or decreased
the immunity for secondary infection to occur.
Bacterial infectious scleritis is more common than other
infectious scleritis. P. aeruginosa has been the often reported
infecting organism [10, 12, 13, 15]. It was reported in
over 50% eyes from Taiwan following pterygium surgeries
[12, 13]. In our cohort, however, Staphylococcus infection
(24.41%) and cataract were the most common surgery
(41.17%). In our series, only one of 17 patients had P.
aeruginosa infection.
One of our coauthors has reported fungal infectious
scleritis in over one of third patients and high incidence
of Nocardia infection from Hyderabad (south central India)
[1]. In this series, we detected fungus in close to a quarter
of patients and Nocardia in close to 20 percent. High
incidence of fungus in both series can be attributed to
the hot and humid climate and the enormous amount of
fungal spore prevalent in the environment [19]. Two of the
three patients with Nocardia scleritis could not recollect any
history of injury although one of them was an agriculturist.
All three patients with Nocardia scleritis required multiple
explorations of the abscess, and one patient (no. 10) (Figures
2(a), 2(b),a n d2(c)) required a scleral patch graft after
resolution of the active infection.
In addition to topical medications, systemic antibiotic or
antifungal was required for 15 patients. Systemic corticos-
teroids were used in patients with bacterial infection (n = 5),
in eyes that developed choroidal detachment (n = 2), and in
the patient who developed exophthalmous (no. 12).
Pyogenic infections of the sclera are often diﬃcult to
eradicate because of poor antimicrobial penetration into the
avascular necrotic sclera; combination of surgery such as
abscess exploration and systemic and topical antimicrobial
therapy yields superior results [1, 13, 20, 21]. SurgicalInternational Journal of Inﬂammation 7
debridementnotonlyfacilitatespenetrationofantibiotic but
also debulks the infected scleral tissue.
We do agree with Lin et al. who suggested mandatory
surgical exploration of the abscess that does not respond to
initial medication to increase the penetration of antibiotic
[13]. Raber et al. reported a “tunnel lesion” on histopatho-
logical ﬁnding in cases of scleral ulcer [22]. Our experience
is similar to Lin et al. who also described the tunnel lesion
and recommended the need of careful exploration to avoid
residual infection [13]. Two (no. 2, 14) of our 7 patients in
this series required multiple surgical intervention and both
of them had “tunnel lesion”.
All 17 patients in this series achieved anatomical success.
Fourteen of 17 patients (82.35%) regained useful vision
(deﬁned as vision ≥20/200). The causes of poor vision in
the remaining three eyes were glaucomatous optic atrophy
(no. 11), chronic retinal detachment (no. 13), and ﬁbrotic
membrane in the pupillary area (no. 17). In an earlier series
by one of our coauthors, one-third of patients had regained
useful vision, but three of 21 eyes were eviscerated and one
eyebecamephthisical[1].Elevenofthe18eyesinHsiaoetal.
series retained useful vision, three had poor vision and four
had to be eviscerated [12]. None of our patients in this series
required evisceration.
Associated uveitis is not uncommon. (66% in Su et al.
series) These inﬂammations lead to formation of pupil-
lary membrane, cataract, and endophthalmitis [10]. Most
patients in our series had low-grade inﬂammation in the
anterior chamber at presentation; severe intraocular inﬂam-
mation occurred in ﬁve patients subsequently. Cataract was
the most common sequel in our series (n = 3). Four patients
who had extension to cornea resolved with corneal scar.
Our series has all weaknesses inherent to all retrospective
studies. Our institution is a tertiary care referral center, so
thereisapotentialforbiastowardsmoreunusualordiﬃcult-
to-control diseases. Nonetheless, we have demonstrated that
a variety of organism can cause scleritis. An early clinical
suspicion of infectious origin, identiﬁcation of the infecting
organism, knowledge of antibiotic susceptibility, and insti-
tution of appropriate medical and/or surgical therapy could
have good tectonic and visual outcome.
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